IP & Achievements

Intellectual Property

• PENAO Pty Ltd enjoys strong patent protection of its asset across multiple jurisdictions, including Australia, Canada, China, the European Union, India, Japan, Switzerland, the UK and the USA.
• Based on its ongoing research and development activities, PENAO Pty Limited anticipates filing further patent applications directed to potential new intellectual property in areas such as: unique formulations, methods of manufacture, and use of PENAO and /or its novel derivatives in combination with other therapeutics.
• Therapeutic areas are not limited to breast cancer; NSCLC; pancreatic cancer; late-stage ovarian cancer; gliomas; cervical cancer; colorectal cancer; neuroblastoma; and other histologically or cytologically confirmed advanced solid tumours refractory to standard treatment, or for which no standard treatment exists.

Achievements

• Clinical trial in 26 Australian patients successfully completed.
• Drug Substance and Drug Product optimisation and development successfully completed by our CMO in India (Aurigene).
• Publication of data in peer-reviewed medical journals.
• Strong IP protection and strategy.
• Recipient of the 43.5% R&D rebate from the Australian government. $625,674.61 received in the past 18 months FY.
• Tight shareholding: Beroni Group Ltd (60%) and the University of New South Wales, Sydney (40%).
• Co-Creator of PENAO, Prof Phil Hogg, is the Company’s CSO.